Wedge Capital Management L L P NC lessened its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 14.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 143,943 shares of the medical instruments supplier’s stock after selling 25,011 shares during the period. Wedge Capital Management L L P NC owned 0.39% of Harvard Bioscience worth $756,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in HBIO. BlackRock Inc. grew its holdings in shares of Harvard Bioscience by 105.3% during the second quarter. BlackRock Inc. now owns 2,934,267 shares of the medical instruments supplier’s stock worth $15,699,000 after purchasing an additional 1,504,668 shares during the last quarter. First Light Asset Management LLC grew its holdings in shares of Harvard Bioscience by 9.4% during the second quarter. First Light Asset Management LLC now owns 5,951,014 shares of the medical instruments supplier’s stock worth $31,838,000 after purchasing an additional 509,724 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Harvard Bioscience by 339.6% during the second quarter. Northern Trust Corp now owns 391,154 shares of the medical instruments supplier’s stock worth $2,093,000 after purchasing an additional 302,184 shares during the last quarter. Royce & Associates LP grew its holdings in shares of Harvard Bioscience by 20.9% during the second quarter. Royce & Associates LP now owns 1,565,000 shares of the medical instruments supplier’s stock worth $8,373,000 after purchasing an additional 270,306 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Harvard Bioscience by 951.3% during the first quarter. Millennium Management LLC now owns 225,619 shares of the medical instruments supplier’s stock worth $1,128,000 after purchasing an additional 204,158 shares during the last quarter. Institutional investors own 73.03% of the company’s stock.
HBIO has been the topic of several research analyst reports. ValuEngine cut Harvard Bioscience from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 22nd. Zacks Investment Research upgraded Harvard Bioscience from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a report on Wednesday, August 1st.
In related news, CFO Robert E. Gagnon sold 8,889 shares of the firm’s stock in a transaction dated Wednesday, August 29th. The stock was sold at an average price of $5.77, for a total value of $51,289.53. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.60% of the stock is owned by company insiders.
Harvard Bioscience stock opened at $4.05 on Friday. The stock has a market capitalization of $155.14 million, a P/E ratio of 81.00 and a beta of 1.29. Harvard Bioscience, Inc. has a 12-month low of $3.00 and a 12-month high of $6.70. The company has a current ratio of 2.83, a quick ratio of 1.49 and a debt-to-equity ratio of 0.73.
Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, October 25th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.04. The business had revenue of $28.71 million for the quarter, compared to analysts’ expectations of $28.50 million. Harvard Bioscience had a positive return on equity of 5.54% and a negative net margin of 4.18%. As a group, equities analysts predict that Harvard Bioscience, Inc. will post 0.12 earnings per share for the current fiscal year.
WARNING: This report was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/10/harvard-bioscience-inc-hbio-shares-sold-by-wedge-capital-management-l-l-p-nc.html.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.
Read More: Discount Rate
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.